These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 15571479)

  • 1. Which drug combination for colorectal cancer?
    Doggrell SA
    Expert Opin Pharmacother; 2004 Dec; 5(12):2621-4. PubMed ID: 15571479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Recent results of irinotecan therapy in colorectal cancer].
    Láng I; Hitre E
    Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy for metastatic colorectal cancer.
    Rosales J; Leong LA
    J Natl Compr Canc Netw; 2005 Jul; 3(4):525-9. PubMed ID: 16038643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
    Kabbinavar FF; Schulz J; McCleod M; Patel T; Hamm JT; Hecht JR; Mass R; Perrou B; Nelson B; Novotny WF
    J Clin Oncol; 2005 Jun; 23(16):3697-705. PubMed ID: 15738537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing time to disease progression of irinotecan and oxaliplatin-based chemotherapies in colorectal cancer patients with liver only metastasis.
    Varol U; Karaca B; Cakar B; Sezgin C; Karabulut B; Uslu R
    Am J Clin Oncol; 2013 Aug; 36(4):388-91. PubMed ID: 22643568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
    Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis.
    Liang XB; Hou SH; Li YP; Wang LC; Zhang X; Yang J
    Chin Med J (Engl); 2010 Nov; 123(22):3314-8. PubMed ID: 21163137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer.
    Komatsu Y; Ishioka C; Shimada K; Yamada Y; Gamoh M; Sato A; Yamaguchi T; Yuki S; Morita S; Takahashi S; Goto R; Kurihara M
    BMC Cancer; 2015 Sep; 15():626. PubMed ID: 26353772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer.
    Grivicich I; Mans DR; Peters GJ; Schwartsmann G
    Braz J Med Biol Res; 2001 Sep; 34(9):1087-103. PubMed ID: 11514832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biotherapy in colorectal cancer].
    Des Guetz G
    J Chir (Paris); 2005; 142(5):291-6. PubMed ID: 16292207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    Loupakis F; Cremolini C; Masi G; Lonardi S; Zagonel V; Salvatore L; Cortesi E; Tomasello G; Ronzoni M; Spadi R; Zaniboni A; Tonini G; Buonadonna A; Amoroso D; Chiara S; Carlomagno C; Boni C; Allegrini G; Boni L; Falcone A
    N Engl J Med; 2014 Oct; 371(17):1609-18. PubMed ID: 25337750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of new agents in the treatment of colorectal cancer.
    Folprecht G; Köhne CH
    Oncology; 2004; 66(1):1-17. PubMed ID: 15031593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.
    Folprecht G; Köhne CH
    Nat Clin Pract Oncol; 2005 Nov; 2(11):578-87. PubMed ID: 16270098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.
    Saltz L; Badarinath S; Dakhil S; Bienvenu B; Harker WG; Birchfield G; Tokaz LK; Barrera D; Conkling PR; O'Rourke MA; Richards DA; Reidy D; Solit D; Vakiani E; Capanu M; Scales A; Zhan F; Boehm KA; Asmar L; Cohn A
    Clin Colorectal Cancer; 2012 Jun; 11(2):101-11. PubMed ID: 22055112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second line therapies move to the forefront in colorectal cancer.
    Miller M
    J Natl Cancer Inst; 1999 Jun; 91(12):998-1000. PubMed ID: 10379961
    [No Abstract]   [Full Text] [Related]  

  • 18. Irinotecan-based regimens in the adjuvant therapy of colorectal cancer.
    Douillard JY
    Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S34-7. PubMed ID: 15871764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of bevacizumab as first-line therapy for colon cancer.
    Marshall J
    Semin Oncol; 2005 Dec; 32(6 Suppl 9):S43-7. PubMed ID: 16399431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA drug approval summaries: oxaliplatin.
    Ibrahim A; Hirschfeld S; Cohen MH; Griebel DJ; Williams GA; Pazdur R
    Oncologist; 2004; 9(1):8-12. PubMed ID: 14755010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.